Filgrastim-ayow - Biologic Drug Details

Summary for filgrastim-ayow

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for filgrastim-ayow

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for filgrastim-ayow Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for filgrastim-ayow Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for filgrastim-ayow Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Filgrastim-ayow

Last updated: February 20, 2026

How does the current market landscape influence filgrastim-ayow?

Filgrastim-ayow, marketed by Amneal Pharmaceuticals, is a biosimilar to Neupogen (filgrastim), a granulocyte colony-stimulating factor (G-CSF). It entered the U.S. market through a prior approval pathway following an abbreviated biologics license application (aBLA). The product gained approval from the FDA in August 2019.

The biosimilar segment has experienced rapid growth driven by patent expirations for originator biologics. The biosimilarization of filgrastim began after Amgen's Neupogen and Novartis's Zarzio (marketed globally) lost exclusivity. The U.S. biosimilar market revenues stood at approximately $334 million in 2022, with projections exceeding $1.6 billion by 2027, according to IQVIA.

Filgrastim-ayow faces competition primarily from branded Neupogen and other biosimilars like Sandoz's Zarxio. Despite price discounts of up to 30-40%, the length of patent protections and formulary placements limit market share gains.

Regulatory and reimbursement environments influence market penetration. CMS codes assigned to biosimilars impact coverage decisions, affecting physicians’ prescribing patterns. State laws also govern substitution policies, affecting biosimilar uptake.

What are the key drivers of revenue for filgrastim-ayow?

Revenue depends on market share, price, and prescribing patterns. Amneal's pricing strategy offers savings of approximately 20-30% compared to the originator. Given the demand for WB and inpatient chemotherapy, the drug targets hospital and outpatient clinics.

In 2022, Amneal reported biosimilar revenues of approximately $150 million globally, with filgrastim biosimilars accounting for a significant portion. Amneal expects to maintain steady growth by expanding formulary acceptance and entering new markets, including Latin America and parts of Asia. However, potential generic and biosimilar entrants could pressure prices.

What is the growth outlook for filgrastim-ayow?

Market analysts project a compound annual growth rate (CAGR) of around 16% for filgrastim biosimilars between 2022 and 2027. The expansion hinges on:

• Increased adoption facilitated by shifts in prescribing habits, especially in outpatient settings.
• Greater acceptance of biosimilars by healthcare providers, driven by policy incentives.
• Emerging markets opening biosimilar pathways, extending revenue opportunities.

Pricing pressures are anticipated to persist due to new biosimilar entries. Amneal's ability to differentiate its product via cost savings and supply chain resilience influences its financial trajectory.

How do regulatory policies impact filgrastim-ayow’s market performance?

U.S. regulatory pathways for biosimilars follow the Biologics Price Competition and Innovation Act (BPCIA). The FDA has approved over 40 biosimilars since 2015. Policies promoting biosimilar substitution and incentivizing biosimilar use enhance market opportunity.

In 2020, the FDA clarified interchangeability standards, which could accelerate substitution at pharmacy level. However, state-level regulations vary; some restrict automatic substitution of biosimilars, limiting swift market expansion.

International regulatory approvals further influence growth. Countries with streamlined biosimilar policies and price controls, such as the UK, EU, and Japan, serve as growth avenues. Filgrastim biosimilars receive approval in multiple countries, but delays in some regions dampen short-term growth.

What are the financial risks and opportunities?

Risks:

• Price erosion due to new biosimilar entries, aggressive discounting.
• Reimbursement policy shifts that favor originator biologics.
• Limited healthcare provider familiarity impacting prescribing patterns.

Opportunities:

• Growing demand in chemotherapy-induced neutropenia management.
• Expansion into emerging markets with younger biosimilar frameworks.
• Contract manufacturing and supply chain efficiencies to reduce costs.

Amneal projects a profitable trajectory by leveraging operational efficiencies and expanding its biosimilar portfolio.

---

Key Takeaways

• Filgrastim-ayow operates within a competitive biosimilar market, primarily challenged by originator and other biosimilar products.
• Revenue growth depends on market share, pricing, biosimilar acceptance, and regulatory environments.
• The CAGR for filgrastim biosimilars is projected around 16% from 2022 to 2027.
• Competitive pressures from new biosimilars and policy shifts present both risks and opportunities.
• Geographical expansion, policy reforms, and strategic pricing underpin future growth prospects.

---

FAQs

1. How does filgrastim-ayow compare price-wise with the originator Neupogen?
   It typically retails at a 20-40% discount, incentivizing formulary switches.

2. What regulatory hurdles does filgrastim-ayow face in international markets?
   Approval delays and differing biosimilar policies can slow international access.

3. How does the FDA define interchangeability, and how does it affect market adoption?
   Interchangeability requires evidence of switching safety and efficacy; approval can increase automatic substitution at pharmacies, boosting sales.

4. What is Amneal’s strategic approach to increasing filament growth?
   Focus on expanding formulary acceptance, entering new markets, and maintaining competitive pricing.

5. What market segments predominantly consume filgrastim biosimilars?
   Hospitals, outpatient clinics, and specialty pharmacies managing chemotherapy-induced neutropenia.

---

References

[1] IQVIA. (2023). Biosimilar Trends Report 2023.
[2] U.S. Food and Drug Administration. (2020). Biosimilar and Interchangeable Products.
[3] Amneal Pharmaceuticals. (2022). Annual Report.
[4] EvaluatePharma. (2022). Biosimilar Market Forecast.
[5] Centers for Medicare & Medicaid Services. (2022). Biosimilar reimbursement policies.